Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience
April 22, 2021 07:30 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, April 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...
Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress
April 20, 2021 18:40 ET
|
Akari Therapeutics Plc
Opening of Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in bullous pemphigoid (BP), a severe dermatological disease with no...
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)
April 12, 2021 10:16 ET
|
Akari Therapeutics Plc
FDA investigational new drug application (IND) now open Clinical sites expected to open for recruitment mid-2021 NEW YORK and LONDON, April 12, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc...
Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma
March 04, 2021 08:30 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, March 04, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...
Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis
February 25, 2021 09:07 ET
|
Akari Therapeutics Plc
A newly published review article in the journal CELLS highlights the role LTB4 plays in the induction of vascular endothelial growth factor (VEGF) damage and retinal inflammation in the eye. Elevated...
Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease
February 01, 2021 09:29 ET
|
Akari Therapeutics Plc
Building on the positive clinical and safety data from its lead drug nomacopan, Akari is developing a second related therapeutic candidate (votucalis) focusing on new clinical targets.Votucalis...
Akari Therapeutics to Participate in Two January Virtual Investor Conferences
January 06, 2021 09:32 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress
December 11, 2020 09:00 ET
|
Akari Therapeutics Plc
Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful U.S. Food and Drug Administration (FDA) and European...
Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
December 11, 2020 08:55 ET
|
Akari Therapeutics Plc
New data accrued from 19 PNH patients treated for over 30 cumulative patient-years show that self-administered nomacopan is well-tolerated and substantially reduces transfusion dependence. Transfusion...
Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease
December 03, 2020 10:00 ET
|
Akari Therapeutics Plc
New data highlight role of leukotriene B4 (LTB4) in the pathophysiology of retinal inflammation and degenerationIn the experimental allergic uveitis (EAU) disease model nomacopan reduced Th17 effector...